Regenicin (Regenicin) Receivables Turnover : 0.00 (As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Regenicin's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Regenicin's average Accounts Receivable for the three months ended in Mar. 2023 was $0.00 Mil.

Regenicin Receivables Turnover Historical Data

The historical data trend for Regenicin's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Receivables Turnover Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Receivables Turnover

Get a 7-Day Free Trial

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Regenicin's Receivables Turnover

For the Biotechnology subindustry, Regenicin's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenicin's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Regenicin's Receivables Turnover falls into.

Regenicin Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Regenicin's Receivables Turnover for the fiscal year that ended in Sep. 2022 is calculated as

	Receivables Turnover (A: Sep. 2022 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Sep. 2022 )	/ (	(Accounts Receivable (A: Sep. 2021 )	+	Accounts Receivable (A: Sep. 2022 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Regenicin's Receivables Turnover for the quarter that ended in Mar. 2023 is calculated as

	Receivables Turnover (Q: Mar. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2023 )	/ (	(Accounts Receivable (Q: Dec. 2022 )	+	Accounts Receivable (Q: Mar. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Regenicin (OTCPK:RGIN) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Regenicin Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Regenicin's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines